PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18980990-9	2008	Importantly, lenalidomide further augmented the Th1 polarization by iNKT cell lines via increased Th1 cytokine production and reduced Th2 cytokine production.	Lenalidomide	13-25	negative elongation factor complex member C/D	Homo sapiens	48-51	
18980990-9	2008	Importantly, lenalidomide further augmented the Th1 polarization by iNKT cell lines via increased Th1 cytokine production and reduced Th2 cytokine production.	Lenalidomide	13-25	negative elongation factor complex member C/D	Homo sapiens	98-101	
30104242-0	2018	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.	Lenalidomide	101-113	negative elongation factor complex member C/D	Homo sapiens	14-17	
33704530-7	2021	A slight increase of T-bet-positive TH1-equivalents was identifiable under lenalidomide.	Lenalidomide	75-87	negative elongation factor complex member C/D	Homo sapiens	36-39	
30104242-6	2018	Within days of starting lenalidomide, T cells increased in the tumor microenvironment and showed Th1-type polarization.	Lenalidomide	24-36	negative elongation factor complex member C/D	Homo sapiens	97-100	
30104242-11	2018	Taken together, our data demonstrate that lenalidomide induced Th1 immunity in the lymph node that is associated with clinical response.	Lenalidomide	42-54	negative elongation factor complex member C/D	Homo sapiens	63-66	
29951065-12	2018	In summary, DCs derived from monocytes in the presence of lenalidomide present a semi-mature phenotype, increased phagocytic capacity, reduced production of proinflammatory cytokines, and the ability to polarize T-cells toward predominant Th1-type responses; these are qualities that might be useful in the development of new immunotherapeutic treatments.	Lenalidomide	58-70	negative elongation factor complex member C/D	Homo sapiens	239-242	
27698446-0	2017	Expansion of Th1-like Vgamma9Vdelta2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.	Lenalidomide	69-81	negative elongation factor complex member C/D	Homo sapiens	13-16	
27889516-7	2017	These results suggest that LEN enhanced the function of DCs generated from patients with multiple myeloma by stimulating the capacity of allogeneic T cells, inhibiting the generation of immunosuppressive cells, inducing naive T cells toward Th1 polarization, and generating potent myeloma-specific cytotoxic T lymphocytes.	Lenalidomide	27-30	negative elongation factor complex member C/D	Homo sapiens	241-244	
27668268-0	2015	Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors.	Lenalidomide	0-12	negative elongation factor complex member C/D	Homo sapiens	23-26	
27668268-5	2015	Lenalidomide increased the anti-tumor activities of XBP1-CTL memory subsets, which were associated with expression of Th1 transcriptional regulators (T-bet, Eomes) and Akt activation, thereby resulting in enhanced IFN-gamma production, granzyme B upregulation and specific CD28/CD38-positive and CTLA-4/PD-1-negative cell proliferation.	Lenalidomide	0-12	negative elongation factor complex member C/D	Homo sapiens	118-121	
23609417-0	2013	Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.	Lenalidomide	81-93	negative elongation factor complex member C/D	Homo sapiens	15-18	
23609417-6	2013	Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes.	Lenalidomide	13-16	negative elongation factor complex member C/D	Homo sapiens	49-52